Next Article in Journal
The Efficacy of Edaravone (Radicut), a Free Radical Scavenger, for Cardiovascular Disease
Next Article in Special Issue
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Previous Article in Journal
(Healthy) Ageing: Focus on Iodothyronines
Previous Article in Special Issue
Molecular and Functional Imaging for Detection of Lymph Node Metastases in Prostate Cancer
Due to scheduled maintaince work on one of the switches in our server center, our websites and may experience short service dirsuptions of up to 5 minutes on 30 January 2015 00:00 PM EST time.
Int. J. Mol. Sci. 2013, 14(7), 13893-13908; doi:10.3390/ijms140713893

Sarcosine as a Potential Prostate Cancer Biomarker—A Review

, 2
, 1,2,3
, 1,2
, 1,2,3
, 1,2
, 4
, 5
, 1,2
 and 1,2,*
Received: 22 May 2013 / Revised: 20 June 2013 / Accepted: 22 June 2013 / Published: 4 July 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [520 KB, updated 19 June 2014; original version uploaded 19 June 2014]   |   Browse Figures
Abstract: Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.
Keywords: cancer of prostate; biomarkers; early diagnostic; prostatic specific antigen; non-invasive markers; urine; amino acids cancer of prostate; biomarkers; early diagnostic; prostatic specific antigen; non-invasive markers; urine; amino acids
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Cernei, N.; Heger, Z.; Gumulec, J.; Zitka, O.; Masarik, M.; Babula, P.; Eckschlager, T.; Stiborova, M.; Kizek, R.; Adam, V. Sarcosine as a Potential Prostate Cancer Biomarker—A Review. Int. J. Mol. Sci. 2013, 14, 13893-13908.

AMA Style

Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, Kizek R, Adam V. Sarcosine as a Potential Prostate Cancer Biomarker—A Review. International Journal of Molecular Sciences. 2013; 14(7):13893-13908.

Chicago/Turabian Style

Cernei, Natalia; Heger, Zbynek; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Babula, Petr; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene; Adam, Vojtech. 2013. "Sarcosine as a Potential Prostate Cancer Biomarker—A Review." Int. J. Mol. Sci. 14, no. 7: 13893-13908.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert